Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed in Global First

by admin July 1, 2024
July 1, 2024
Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed in Global First

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which may be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to advise that it has successfully and safely completed the world’s first participant dosing using TRP-8803 (IV-infused psilocin) in a patient in Adelaide, South Australia.

  • Completion of first participant dosing for TRP-8803 (IV-infused psilocin) Healthy Human Volunteer Study – Trial being undertaken alongside CMAX Clinical Research in Adelaide and marks a world-first in psychedelic treatment
  • Study aims to refine and optimise dosing and infusion rates of TRP-8803 to achieve precise blood levels of psilocin with an acceptable pharmacokinetics profile in up to 12 participants to determine TRP-8803’s safety in humans – results will inform TYP’s Phase 2a patient study pipeline
  • Participant successfully underwent psilocin infusion over 140 minutes, progressed well through treatment and was discharged on completion
  • TRP-8803’s potential advantages include a significant reduction in onset of the psychedelic state, more precise control of the depth and duration of the experience and a reduction in the duration of the intervention to a commercially feasible timeframe
  • Successful first participant dosing reinforces management confidence in TRP-8803 and its potential
  • Trial expected to completed during Q3 2024 with results to be reported thereafter – Positive results will provide Tryp with the potential to advance its clinical trial pipeline across multiple conditions
The participant was administered TRP-8803 (IV-infused psilocin) as part of the Company’s planned Healthy Human Volunteer Study, which is being undertaken by CMAX Clinical Research in Adelaide. The trial is an open-label design, undertaken with therapist support and aims to refine and optimise dosing and infusion rates of TRP-8803 to achieve precise blood levels of psilocin with an acceptable pharmacokinetics profile in up to 12 participants and to determine its safety prior to additional clinical studies which will be focused on particular need states.

Tryp advises that the participant was provided with TRP-8803, the Company’s innovative IV-infused psilocin solution on Friday, 28 June for approximately 140 minutes and progressed through the treatment safely. The participant was discharged after dosing follow-up was completed.

TRP-8803, Tryp’s lead program alleviates a number of significant shortcomings of oral psilocybin therapy. Potential advantages of the Company’s IV-infused psilocin solution include a significant reduction in the time to onset of the psychedelic state, more precise control of the depth and duration of the psychedelic experience and a reduction in the overall duration of the intervention to a commercially feasible timeframe.

The Company will continue to work alongside CMAX Clinical Research to deliver the solution to the additional participants over the coming weeks. Tryp anticipates to receive interim results from the trial during Q3 2024, which will provide a greater understanding of the solution’s potential in humans.

Management commentary:

Tryp Chief Executive Officer, Mr. Jason Carroll said: “We are very pleased to have completed the world’s first TRP- 8803 treatment in a patient in Adelaide. Pleasingly, the maiden participant was delivered the infusion safely and was discharged on treatment conclusion, which provides management with confidence of TRP-8803 and the completion of this Healthy Human Volunteer Study.

“The trial, which being undertaken alongside CMAX is an incredibly important initiative for Tryp, as it will provide us with data highlighting TRP-8803’s safety in humans at escalating doses. This will form the basis of the Company’s clinical trial pipeline into other indications and ultimately our regulatory engagement.

“The Company expects that up to 12 participants to undertake infusion over the coming weeks and we look forward to provide further updates as the trial advances.”

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Investor Webinar – 3pm AEST Tuesday 2 July
next post
Jill Biden’s ex-husband calls her out for defending ‘struggling’ Joe Biden, ‘keeping him in the race’

Related Posts

Rapid Increases Land Holding by 26 X

June 11, 2025

Harvest Gold Identifies 15 Primary And 10 Secondary...

June 13, 2025

Crypto Market Recap: Senator Cruz Supports Bitcoin Mining...

April 3, 2025

Dynasty Gold Announces 2024 Annual General Meeting Results...

October 11, 2024

Major Finland Gold Transaction

April 11, 2025

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment...

October 12, 2024

New Generation Atomic Layer Deposition Machine Procured

November 11, 2024

HiPurA® HPA Pilot Plant Early-Stage Commissioning Commenced

June 29, 2024

Radiopharm achieves Nasdaq listing of ADS

November 27, 2024

Canadian Investment Regulatory Organization Trade Resumption – STUD

July 8, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Trump welcomes Polish president with flyover tribute to fallen fighter pilot

      September 4, 2025
    • Epstein victims press lawmakers to support bill to release hidden files, say Americans will be ‘appalled’

      September 4, 2025
    • Trump hits back at reporter who said he’s taken ‘no action’ against Russia

      September 4, 2025
    • Trump’s political advisers huddle with House GOP over rebranding of the big beautiful bill

      September 4, 2025
    • SCOOP: House GOP eyes more Medicaid reforms in second budget reconciliation bill

      September 4, 2025

    Categories

    • Business (1,098)
    • Investing (2,969)
    • Politics (3,619)
    • Stocks (1,155)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved